hotspot -WSS

hotspot

author：hotspot 2025-09-30 19:03:24 - browse：8339

SAN DIEGO — After starting off the year with lower revenue projections than market analysts had hoped for, San Diego-based genomics giant Illumina lowered expectations again on Wednesday, forecasting annual growth of 1% compared to the previous year.

The market’s response was swift. Minutes after the company issued its press release, shares in Illumina dipped from $184.49 to below $172 during after-hours trading.

In its release, Illumina noted that it expects revenue from the company’s core business to be essentially the same this year compared to last, and that it expects revenue from Grail, the cancer diagnostics company that Illumina acquired for $8 billion in the fall of 2021, to remain in the range of $90 and $100 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Profiling embryos to choose those with higher IQs is almost a reality

WSS

Orchard's therapy for neuron disease in children wins FDA approval

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

U.K. researchers warn about biases in medical devices, algorithms

Medicare Advantage coverage denials need scrutiny, senators say

Male doctors called my cancer incurable. A female doctor showed it wasn't

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

hotspot

hotspot

Wikipedia

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Bright Health sells Medicare Advantage business to Molina

Hospital chaplains balance Covid safety with patients’ spiritual needs

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

In Memoriam: Notable people who died in 2023

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

At least 13 dead in Texas as scorching temps continue

Male doctors called my cancer incurable. A female doctor showed it wasn't

leisure time

Argenx readies a blockbuster opportunity with drug for autoimmune disease

SCOTUS questions limit to govt efforts to fight misinformation

Life science postdocs should get big pay hike, NIH panel says

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Future doctors should be trained to promote social change

Intermittent fasting comes with a heart risk? Not so fast

entertainment

hotspot

hotspot

focus